Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A clinical trial of BBP-418 for the treatment of Limb-Girdle Muscular Dystrophy Type 2i (LGMD2i)

Next Previous
Trial Profile

A clinical trial of BBP-418 for the treatment of Limb-Girdle Muscular Dystrophy Type 2i (LGMD2i)

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 21 Mar 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ribitol (Primary)
  • Indications Limb girdle muscular dystrophies
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors ML Bio Solutions

Most Recent Events

  • 14 Mar 2022 According to a BridgeBio Pharma media release, the company is presenting data from this trial in a poster at the Muscular Dystrophy Association (MDA) 2022 Annual Meeting 2022.
  • 11 Jun 2020 According to a BridgeBio Pharma media release, in March 2020, the U.S. Food and Drug Administration (FDA) approved its Investigational New Drug (IND) application for BBP-418.
  • 11 Jun 2020 According to a BridgeBio Pharma media release, the company is enrolling subjects in this study in collaboration with the GRASP-LGMD consortium based at Virginia Commonwealth University, which is led by Nicholas Johnson, M.D., M.S.C.I.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top